GFM
XERS icon

GF Fund Management’s Xeris Biopharma Holdings XERS Stock Holding History

GF Fund Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.5K Buy
3,710
+450
+14% +$2.98K ﹤0.01% 494
2025
Q4 		$25.6K Sell
3,260
-214
-6% -$1.68K ﹤0.01% 480
2025
Q3 		$28.3K Sell
3,474
-343
-9% -$2.28K ﹤0.01% 449
2025
Q2 		$17.8K Hold
3,817
– – ﹤0.01% 512
2025
Q1 		$21K Buy
3,817
+687
+22% +$2.77K ﹤0.01% 499
2024
Q4 		$10.6K Buy
+3,130
New +$10.1K ﹤0.01% 538

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GF Fund Management's XERS Position: Q1 2026 in Review

GF Fund Management increased its Xeris Biopharma Holdings (XERS) stake by 14% in Q1 2026, buying an estimated $2.98K and bringing the position to 3,710 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #494.

GF Fund Management first reported a position in XERS in Q4 2024 and has held it in 6 quarters since. The position peaked at $28.3K in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • GF Fund Management held 3,710 shares of Xeris Biopharma Holdings worth $21.5K as of Q1 2026.
  • GF Fund Management bought 450 Xeris Biopharma Holdings shares in Q1 2026, an estimated $2.98K.
  • Xeris Biopharma Holdings made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #494 holding.
  • GF Fund Management first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Xeris Biopharma Holdings position peaked at $28.3K in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.